The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GI Malignancies Debate 2022 | The role of HIPEC in peritoneal mesothelioma, GI and ovarian cancers
Deepa Magge, MD, FACS, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides an overview of hyperthermic intraperitoneal chemotherapy (HIPEC), a procedure designed to treat a range of cancers. Patients initially undergo surgery and heated chemotherapy drugs are directly applied to remove any remaining tumors. HIPEC is typically administered in patients with peritoneal mesothelioma, appendix, colorectal, and ovarian cancer. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
